A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study.
Yusuke ChiharaTakayuki TakedaYasuhiro GotoYoichi NakamuraYuko Tsuchiya-KawanoAkira NakaoKeisuke OnoiMakoto HibinoMinoru FukudaRyoichi HondaTakahiro YamadaRyusuke TaniguchiSinjiro SakamotoKoji DateSeiji NagashimaShigeru TanzawaKoichi MinatoKoichi NakataniMiiru IzumiTakayuki ShimoseJunji KishimotoJunji UchinoKoichi TakayamaPublished in: The oncologist (2022)
Although this study did not meet the primary endpoint, osimertinib was tolerable for elderly patients with EGFR mutation-positive advanced non-small cell lung cancer. (Japan Registry of Clinical Trials [JRCT] ID number: jRCTs071180007).